Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)

NCT02684058 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT02684058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02684058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 28, 2017
Completion date
April 28, 2023
Enrollment
151 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic ganglioglioma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma, angiocentric glioma, astrocytoma, central neurocytoma, cerebellar iponeurocytoma, chordoid glioma of third ventricle, desmoplastic infantile astrocytoma and ganglioglioma, diffuse astrocytoma, dysplastic gangliocytoma of cerebrellum, extraventricular neurocytoma, gangliocytoma, ganglioglioma, giant cell astrocytoma, glioblastoma, oligodendroglioma, childhood, papillary glioneuronal tumor, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, rosette-forming glioneurona tumor